ArticleJournal, genetic engineering & biotechnology2025
Integrative multi-omics analysis identifies genetically supported druggable targets for inflammatory bowel disease.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), represents a set of chronic, immune-mediated gastrointestinal disorders with increasing global prevalence. Current therapeutic options are limited, highlighting the need for novel drug targets.
objectiveTo systematically identify druggable genes with potential causal roles in IBD through integrative multi-omics analyses, leveraging genetic, transcriptomic, and epigenomic datasets.
methodWe implemented summary-data-based Mendelian randomization (SMR) to assess the causal relevance of druggable genes in IBD, using large-scale genome-wide association study (GWAS) data from the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC). Replication analyses were performed in the FinnGen cohort. Genetic instruments for druggable genes were derived from the methylation and gene expression levels. To strengthen the causal inference, Bayesian colocalization was applied to distinguish true causal loci from linkage between candidate druggable genes and IBD. Phenome-wide association studies (PheWAS), in silico drug repurposing predictions, and molecular docking simulations were conducted to implicate the possibility of targeted therapeutic drugs for future clinical applications.
resultsThe study identified Thrombospondin-3 (THBS3), Retinoic Acid Receptor-Related Orphan Receptor C (RORC), and Tumor Necrosis Factor Receptor Superfamily Member 25 (TNFRSF25) as potential drug targets for IBD and its subtypes. These genes showed consistent associations with IBD across different biological levels and replication datasets. Molecular docking analyses predicted candidate drugs, including AM580, Dasatinib, 25-Hydroxycholesterol, Medroxyprogesterone acetate, 3,3'-Diindolylmethane, and Hesperidin, which exhibited strong binding affinities to the target proteins.
conclusionOur multi-layered omics framework provided genetically anchored evidence for the role of THBS3, RORC, and TNFRSF25 as druggable targets in IBD. The identified candidate drugs offered new avenues for therapeutic intervention. Further clinical validation is warranted to harness these targets for the development of effective IBD treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.